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Research Article

Development and Evaluation of Quercetin Dispersible Tablets
Roopali M Shetake, Basavaraj K Nanjwade*, Arindam Basu Sarkar, Teerapol Srichana, Kishor A Bellad
Email: nanjwadebk@gmail.com

Abstract
Quercetin is an anti-oxidant agent, commonly used as an anti-inflammatory, anti-rheumatic, anti-diabetic,
anti-ulcer, and is also used for the treatment of several cancers such as bladder, breast, stomach, lung, ovaries,
thyroid, soft tissue sarcoma, prostate and others. In the present study, dispersible tablets of Quercetin, using
three different disintegrants such as Crospovidone, Amberlite IR P 88 with different ratios, and complexatation
done with Soluplus by Hot Melt Extrusion (HME) Method, was prepared and the solubility of Quercetin was
increased. All formulations were studied in terms of pre-compressional parametres (flow properties) such as bulk
density, tapped density, angle of repose, Carr’s index and post compressional studies such as weight variation
test, disintegration time, dispersion time, friability test, drug release and study. Optimized formulation F6 was
evaluated for pharmacokinetics parametres, anticancer activities and stability studies as per ICH guidelines.
Key words: Anticancer Activity Study, Dispersible Tablets, Evaluation Parametres, Pharmacokinetics Parametres,
Quercetin, Stability Study

1. Introduction
A system in which the drug product is in a form of
tablet, which disintegrates and dissolves within a
minute or in a few seconds after administration is
known as dispersible tablet system. Therefore, in
this type of system, the drug bioavailability might
be greater than a conventional oral dosage form.
Dispersible tablet system consists of a disintegrating
and super-disintegrating asset in which water enters
the tablet matrix quickly, which in turn results in a
generation of porous structure that results in a fast
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disintegration. Hence, for the development of the
dispersible tablet, it comprises the exploitation of
tablet matrix that is made up of a porous structure by
the incorporation of suitable disintegrating agents,
or it may be done by adding hydrophilic excipients
in the formulation. The development of the tablet
can also be obtained by using a direct compression
method.1-3
In industries, direct compression method is generally
used for developing dispersible tablets as it is simple
and cost–effective due to the usage of conventional
equipment and commonly used excipients, as these
are the limited processing steps that are beneficial
to this technique. Solubilization depends on single
or multiple actions of disintegrant, hydrophilic
excipients and effervescent agents in the directly
compressed tablets. The name ‘Quercetin’ came from
the Latin word quercetum, which means oak – forest
quercus oak. Bioflavonoids was firstly discovered
by Albert Szent Gyorgyi in 1930; he also won the
Nobel Prize for the same. Over the past 30 years
researchers have been extensively studying about
Quercetin (3,3’,4’5,7-pentahydroxy flavone), which
is a natural unique bioflavonoid.5 The synonyms
of Quercetin are Quercetin, sophretin, meletin.
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It is formed as the glycoside Quercitrin in the
bark of quercus tinctoria (American Oak). Several
years ago, it was found that Quercetin causes DNA
mutation in bacteria, which was a possible sign that
it may cause cancer. It was also discovered that in
the Quercetin plant, leaves, barks, rinds, seeds and
flowers contain a pigment called polyphenolics,
which is found associated with Vitamin C that
imparts synergistic effects. Flavoinds and Vitamin
C both act as antioxidants; therefore, both prevent
the Quercetin plant from oxidizing. Because of this,
Quercetin became a subject of scientific reports
over the last three decades, and it also showed the
greatest activity among several flavonoids that
have been proved in several experimental models.
Flavonoids and Vitamin C are also important for
human health.7 It has been reported as a complete
package, i.e., it possesses biological, pharmacological
and medical applications, and is also reported as
one of the most potent antioxidants. The prime
objective of this study is to increase solubility and
bioavailability of Quercetin by complexatation with
a polymer and using different disintegrates by the
direct compression method.
2. Materials and Methods
Quercetin was procured from Ozone International,
Mumbai, India. Soluplus was obtained from BASF
India Ltd, Mumbai. Amberlite IRP88 was obtained
from Cipla Pvt Ltd, Mumbai. Crospovidone was
obtained from Ozone International, Mumbai. Sodium
starch glycolate was obtained from S D Fine Chem
Ltd, Mumbai. Magnesium stearate was obtained
from Thomas Baker, Mumbai. Microcrystalline
cellulose was obtained from Loba Chemie Pvt Ltd.
Sodium saccharin was obtained from Central Drug

House Ltd, Delhi. All other chemicals used were of
laboratory grade.
2.1 Preparation of Drug Complex with Soluplus
Polymer by Hot Melt Extrusion Method:
Solid solutions of Quercetin using Soluplus were
prepared by hot melt extrusion in a Thermo Fisher
Polylab twin-screw extruder. The Drug: polymer
ratio was maintained at 1:1. Extrusion parametres
adjusted were as follows:
• RPM : 80°C
• Bar Pressure : 40°C
• Temperature : 60°C - 150°C
Zone Zone 3 Zone
2
4

Zone
5

Zone
6

Zone
7

Zone
8

Die

60°C 100 °C 120°C 140°C 150°C 150°C 150°C 150°C

2.2 Formulation of dispersible tablets:
The dispersible tablets (average weight 750 mg)
of Quercetin were prepared by direct compression
technique using three different disintegrants
– Crospovidone, Sodium starchglycolate, and
Amberlite IR P88. The composition of dispersible
tablets is given in Table 5. Microcrystalline cellulose
was used as diluents.
•

Procedure:
Separately, all the formulation ingredients were
passed through sieve no. 30 mesh. To obtain
a uniform mixture, the drug and diluent were
mixed gradually in a small portion. After a
uniform mixture was obtained, a flavouring
agent and a lubricant were added at the end and
it was again mixed thoroughly. This blend was
then compressed in a 750 mg dispersible tablet

Table 1: Composition of Quercetin dispersible tablet using three different disintegrants

6

Sr. No

Ingredients

1
2
3
4
5
6
7
8

Quercetin and Soluplus complex
Crospovidone
Sodium starchglycolate
Amberlite IRP88
Sodium saccharin
Magnesium stearate
Talc
Microcrystalline cellulose
Total

F1
mg
400
100
15
7.5
7.5
220
750

F2
mg
400
200
15
7.5
7.5
120
750

F3
mg
400
100
15
7.5
7.5
220
750

F4
mg
400
200
15
7.5
7.5
120
750

F5
mg
400
100
15
7.5
7.5
220
750

F6
mg
400
200
15
7.5
7.5
120
750

Category
Antioxidant
Disintegrant
Disintegrant
Disintegrant
Sweetening agent
Lubricant
Guidant
Diluent
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by using 10 mm flat punch rotary punching
machine.
3. Evaluation of Quercetin dispersible tablets
3.1 Other preformulation studies
Information gained from the preformulation studies
of the API is shown in Table 8. From the obtained
results, it is determined that the characteristic flow
properties of the API is poor. So, it necessitates
the need of altering its flow properties in a certain
direction to gain uniform weight.9,10
3.2 Apparent solubility study
To overcome the low solubility of Quercetin,
apparent solubility, a study of Quercetin was carried
out using complexation with soluplus polymer.
It was determined by adding an excess of Quercetin
and Quercetin-Soluplus complex to 5ml of water
or in octanol in sealed containers made up of glass
at room temperature (25-30ºC). This complex
was agitated for 24 hours and then centrifuged
for 20 minutes at 1000 rpm to remove any excess
Quercetin. After centrifugation, the supernatant was
collected by filtering the mixture with a membrane
filter (0.4 µm), and then to the collected supernatant
(1 mL), 9 mL distilled water was added for dilution.
After dilution these samples were measured at 322
nm UV spectrophotometrically.11

3.3 Post-compressional studies:
Post – compressional studies were conducted on
dispersible tablets, which include parametres such as
weight variation, hardness, friability, disintegration
time, wetting time and content uniformity.12
3.4 In vitro drug release studies
Drug dissolution studies were carried out by using
USP apparatus 2 (paddle type) at 37 oC ± 0.50, in
which phosphate buffer pH 6.8 (900 mL) was used as
a dissolution media by keeping paddle rotation speed
at 50 rpm, then the absorbance was measured at 265
nm spectrometrically.
3.5 Drug content:
For determining the drug content, 10 tablets
were weighed precisely and crushed. The amount
equivalent to 200 mg of Quercetin was balanced
accurately and mixed in 6.8 pH phosphate buffer.
This mixture was then filtered through Whatman
filter paper. The filtered solution was then analyzed
for drug content by UV-spectrophotometre at 265
nm. Phosphate buffer pH 6.8 was used as a blank.3
3.6 In Vivo studies
3.6.1 In Vivo pharmacokinetic studies
Pharmacokinetic study was conducted on Albino
rats (weighing around 170 to 200 gm). The animals
were divided into two groups (where n=6). They

Table 2: Result of preformulation study of Quercetin
Formulation
Code
F1
F2
F3
F4
F5
F6

Angle of
Repose (00)*
18.43±0.21
13.76±0.35
15.78±0.45
16.69±0.28
19.24±0.34
25.34±0.51

Bulk Density
(gm/cm3)*
0.405±0.03
0.414±0.05
0.418±0.08
0.420±0.016
0.455±0.04
0.430±0.09

Tapped density
(gm/cm3)*
0.440±0.011
0.418±0.024
0.424±0.041
0.448±0.029
0.460±0.03
0.435±0.05

Hausner’s
Ratio*
1.08±0.028
1.03±0.023
1.08±0.024
1.06±0.026
1.11±0.021
1.01±0.023

Carr’s
Index (%)*
0.7±1.62
0.4±1.32
0.6±1.54
2.8±1.42
0.5±1.21
0.5±1.86

* Values in ± Standard Deviation where n=3
Table 3: Result of postcompressiotional study of Quercetin dispersible tablet
Formulation Hardness Kg/
cm
F1
3.51±0.21
F2
3.48±0.35
F3
3.74±0.42
F4
3.23±0.62
F5
3.56±0.12
F6
3.73±0.41

Friability (%)
0.61
0.52
0.61
0.53
0.52
0.43

Weight Variation
(%)
747.90 ±0.28
744.47 ±0.30
751.20 ±0.06
749.59 ±0.25
747.89 ± 0.45
749.90 ± 0.09

Wetting Time in
Sec.
25.22 ± 1.41
24.90 ± 0.21
24.88 ±0.47
23.28 ±0.25
24.25 ±0.51
22.58 ±0.24
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Disintegration
Time in sec.
27.29 ±0.25
26.25 ±0.41
25.00 ±0.65
24.05 ±0.47
26.00 ±0.51
23.05 ±0.24

Drug
content
98.73
100.97
103.50
101.70
100..69
103.71
7
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were given Quercetin dispersion solution of a tablet
orally. Blood samples was collected from the tail
vein of the rats at 5-minute, 10-minute, 15-minute,
30-minute, 45-minute and 60-minute intervals after
the administration of the drug. The collected blood
samples were centrifuged for 10 minutes at 3000
rpm. After the centrifugation, the clear solution
(supernantant) was collected in a tightly sealed
plastic tube containing heparin (anti-coagulant
agent). This was stored in – 20 °C till analysis. The
pharmacokinetic parametres such as the area under
the curve (AUC), peak plasma concentration (Cmax)
and the time to attain peak concentration (tmax)
were determined by plotting the graph between
plasma concentration vs time. To determine the
elimination rate of the drug was constant (Kel), the
semi logarithmic plot of plasma concentration vs
time was plotted, whereas the elimination half-life
(t1/2) was determined by using the formula: t1/2 =
0.693/Kel. For determining AUC statistically, one–
way ANOVA at 0.05 levels was applied in a graph
pad prism version 5.01 software.
3.6.2 In Vivo pharmacodynamic studies
This study was carried out to check the anticancer
activity on human lung carcinoma (Cell line- A549).
Experiments were performed on cell line-A549
human lung carcinoma at the concentration of 10
µgm, 20 µgm, and 30 µgm. All the experiments
were supported in agreement with the procedures
approved by the Institutional Animal Ethics
Committee (IAEC).
MTT Test
Materials and equipment
• 5 mg MTT (3-(4, 5 dimethyl thizol-2-yl)-2,
5-diphenyl tetrazolium bromide) solution in
PBS. Sterilized by filtration. Stored in dark at 4
0
C. Stable for a month.
• 96-Well plates
• Multichannel pipettes
• Microplate reader equipped with a 490 nm filter.
Experimental procedure
• After the xenobiotic cell treatment, the
monolayers of the cells were washed gently
with luke warm phosphate buffer saline pH 7.4
using a multichannel pipette.
8

•

MTT solution contained in culture media (100
µl) was added to each well in a 10:1 ratio. It is
recommended to have some wells in the plate
without cells but incubated with MTT solution
in order to have blanks of the reading.

•

Depending on the cell weight and its activity,
cells are kept for 1–3 L in volume in a cell
incubator.

•

Incubation medium is removed carefully.

•

Dimethyl sulphoxide (100 uL) was added onto
the plate and then the plate was shaken gently
to resuspend the formazan which was formed in
MTT assay. Then we wait until a homogenized
colour is formed.

Reading of results and calculation
• After resuspending the formazan the absorbance
was read at 490 nm of all the wells and blanks.
•

The mean absorbance of each wells was
calculated by subtracting the blank reading.
Then, the results were normalized bearing in
mind that the control wells would be 100%, i.e.,
maximum absorbance obtained articulating the
results as percentage of controls.

Using the appropriate method of calculation,
normally log it transformation, IC 50 and IC10 can
be estimated.15
3.7 Stability studies
Procedure:
Stability studies of API as well as the drug product
is necessary and it’s a major criteria in determining
the rationale design and evaluation of dosage form
and their stability for accepting the drug product.
There are three different types of stability studies
such as i) real–time stability studies; ii) intermediate
type; iii) accelerated stability studies. As real–time
stability studies is inconvenient to carry out as
it takes more time to get completed, accelerated
stability studies came into picture. Therefore, in
the present study, the drug product was exposed to
normal conditions of temperature and humidity, and
for accelerated studies the drug product was stored
under extreme conditions as per the ICH guidelines.

Manipal Journal of Pharmaceutical Sciences | September 2019 | Volume 4 | Issue 2

https://impressions.manipal.edu/mjps/vol5/iss2/2

4

Shetake et al.: Development and Evaluation of Quercetin Dispersible Tablets
Nanjwade KB, et al: Development and Evaluation of Quercetin Dispersible Tablets

One month accelerated stability study was conducted
at 40 ± 2 0C and RH 75 % ± 5 %. After the period of
one month the tablets were withdrawn and analyzed
for physical characterization, In Vitro release study
and drug content.16
4. Results and Discussion
4.1 Compatibility study
IR spectroscopy of Quercetin (FTIR)
This study was conducted to evaluate the compatibility
of API with polymers and other excepients of
formulation F4 and F6. The IR spectra of API was
found to be the same as that of the standard spectra.
The samples were put on KBR plates. The FTIR
spectra were recorded at 1cm-1 resolution with the
range of 400 to 4000 cm.117 Characteristic peaks of
the pure drug as aromatic C–H stretching (3382.64
cm-1, C=O (Keto) Stretching (1667.31 cm-1)), OH
(hydroxyl) stretching (3382.64 cm-1), OH (hydroxyl)
bending (1457.72 cm-1), =C-H bending (1006.16
cm-1), C=C stretching (1515.98 cm-1), and C-O-C
stretching (933.33 cm-1). So, it shows the presence of
the drug in the Soluplus and other excipients. Figure
1 shows the IR spectra of pure Quercetin, physical
mixture of drug and polymers F4 formulation and
F6 formulation, and confirms the compatibility of
drug with the polymer. The characteristic peaks
of the pure drug were compared with the peaks
obtained from the combinations that are depicted in
Figure 1.

Figure 1: IR spectra of, physical mixture of drug and polymers,
formulation F4, formulation F6 and pure drug Quercetin.

4.2 Differential scanning calorimetric
Differential scanning calorimetry is a fast and reliable
method to detect drug excipient compatibility to
provide maximum information on regarding the
possible interactions. In DSC an interaction is
concluded by the elimination of endothermic peaks,
appearance of new peaks and changes in various
parametres of thermogram (like peak shape, its
onset, peak temperature/melting point and relative
peak area or enthalpy).
Analysis (DSC)
The generated thermograms of DSC showed
endothermic peaks of pure (P) Quercetin 314.33 oC,
Formulation F6 235.01 0C and 225.05 oC for F4 were
observed as shown in Figure 2.

Figure 2: Differential scanning calorimetric graphs of pure (P)
Quercetin drug, formulation F6 and formulation F4.
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4.3 X-Ray diffraction analysis (XRD)
The physical status of Quercetin soluplus complex
(F4 and F6) was compared with that of pure
Quercetin (P) by XRD analysis. In Figure 3,
Quercetin exhibit a lot of distinct peaks that are
traits of a crystalline structure. The Quercetin
soluplus complex (F4 and F6) also present a number
of distinct peaks. It indicated that the drug was not
completely amorphous in nature. The graph shown
in Figure 3.17.
4.4 Precompressional studies
Table 2 Result of preformulation study of Quercetin.
4.5 Post compressional Studies
Disintegration time was found between 23.05,
24.05, 25.00, 26.25 and 27.29 (seconds) in six
formulations F6, F4, F3, F5, and F1, respectively.
By the disintegrating time , it is shown that F6
formulation disintegrate faster compared to the
other formulations. Hardness was obtained as 3.25
kg/cm 2, 3.48 kg/cm 2, 3.51 kg/cm 2, 3.56 kg/cm 2,
3.73 kg/cm 2, and 3.74 kg/cm 2 in formulations F4,
F2, F1, F5, F6 and F3, respectively.

the targeted site. Only 3.44 µg/ml of Quercetin
is soluble in aqueous media. Therefore, to improve
its solubility in aqueous media, it is prepared in
a complex form with Soluplus using HME, as
mentioned in Table 7. By this, the solubility of
Quercetin was increased by 10 folds i.e., 30.81 µg/ ml.
HME increased the solubility of the drug by action
on wetting time, disintegration time and dispersion
time. The Soluplus complexatation increased the
solubility behaviour of the herbal actives due to the
amphiphilic and amorphous nature of the product.
The complex showed enhanced solubility and may
improve absorption across the biological barriers
for improving oral bioavailability of the active
component.

Table 4: Solubility study (H2O) at 25°C
Sample

Aqueous Solubility (µg/ml)

Quercetin
Quercetin complex

3.44
30.81

4.6 Solubility studies
The log P value of Quercetin is log P; 1.82 ± 0.32,
which indicates the enormous hydrophobicity of
Quercetin, but this API is also slightly soluble in
aqueous media. Due to the poor solubility nature of
Quercetin, it prevents the absorption/permeation
across intestinal epithelial cells of GIT, which in
turn results in low bioavailability of the drug at

Figure 3: X-Ray powder diffraction studies for Quercetin (P), F6,
F4.

Table 5: Drug released profile of formulation of Quercetin dispersible tablet.
Formulation

F1
F2
F3
F4
F5
F6
10

% Release
after 5
min
20.21
22.58
10.25
14.25
34.24
38.09

% Release
after 10
min
25.52
26.48
13.27
18.48
39.54
44.08

% Release
after 15
min
28.05
30.85
15.84
24.45
42.94
53.84

% Release
after 20
min
35.24
37.58
22.58
26.45
56.35
66.66

% Release
after 30
min
38.78
40.24
27.56
30.47
65.78
72.72

% Release
after 40
min
41.24
44.84
32.48
32.85
70.89
75.76

% Release
after 50
min
43.84
47.18
37.84
40.45
85.28
88.70

% Release
after 60 min
49.28
51.86
40.57
41.25
95.25
98.25
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Table 7: Log plasma concentration V/S time profile.
Sr. No
1
2
3
4
5
6

Figure 4: % Drug release V/s time for the Quercetin formulation
F1 to F6 In vitro release profile

Time in
minutes
5
10
15
30
45
60

Log plasma concentration of
formulation F6 in ngm
1.778
2.0
1.9030
1.812
1.6989
1.544

4.7 In vitro drug release studies
In vitro release study was carried out for Quercetin
dispersible tablet in phosphate buffer pH 6.8 for one
hour using dissolution apparatus type USP XXIII.
In the present investigation, Quercetin dispersible
tablets were prepared in six formulations varying
in two concentrations; one 100 mg and the other
200mg, using three types of super disintegrants
such as Crospovidone, Sodium starch glycolate, and
Amberlite IRP88, respectively. From in vitro drug
percentage release, it was shown that F6 formulation
gives a good percentage of drug release compared
to the rest of the formulation.
5. In Vivo Studies

Figure 5: Plasma concentration V/s time profile

Figure 6: Log plasma concentration V/S time profile
Table 6: Plasma concentration V/S time profile.
Sr.
No
1
2
3
4
5
6

Time in
minutes
5
10
15
30
45
60

Plasma concentration of
formulation F6 in ngm
60
100
80
65
50
35

5.1 Vivo pharmac\okinetic studies
Pharmacokinetic study was conducted on rats with
Formulation F6 and the pure drug. The results for
the Plasma concentration v/s time profile are shown
in Figure 14, and the log plasma concentration
v/s time as shown in Figure 15, pharmacokinetics
parametres are shown in Table 17.
5.2 In-vivo pharmacokinetic analysis
Pharmacokinetic parametres were estimated by
plotting the graph between the plasma concentration
vs. time. After plotting the graph AUC, Cmax,, tmax was
obtained by the same graph plot. Then, to determine
the elimination rate, constant (Kel), the semi –
logarithmic plot was plotted between the plasma
concentration vs time. To calculate the elimination
half–life t1/2 = 0.693/Kel., this formula was used. To
statistically calculate AUC one-way, ANOVA was
applied at 0.05 level intervals in the graph pad prism
software version 5.01.14 The results for the plasma
concentration v/s time profile are shown in Figure
5 and the obtained pharmacokinetics parametres are
shown in Table 6.
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Figure 7: 96 well plates
Figure 9: In vitro drug release study of F6 formulation before
and after stability at 25 o C.

Figure 8: In vitro drug release study of F6 formulation before and
after stability at 4 o C.
Table 8: Pharmacokinetic parametres of Quercetin.
Pharmacokinetic parametres

Formulation F6

C max (ng/ml)

100

T max (minute)

10

AUC (ng/minute/ml)

633.66

K el

0.178

t

4

-1
1/2(hr )

5.3 In Vivo pharmacodynamic analysis
QF: Quercetin F6 Batch Formulation
IC50: Inhibiting Concentration
O.D: Optical Density
QF , IC50, O.D used in Table 9

Figure 10: In vitro drug release study of F6 formulation before
and after stability at 37 o C.

6. Stability study
In this study, the accelerated stability studies for
one month were conducted on the final optimized
formulation (F6) as per the ICH guidelines at
4oC±2oC/60%RH ±5%, 25ºC±2 oC/65%RH ±5
% and 37o C ±2oC/65%RH ±5%. After one month
the tablets were withdrawn and analyzed for
physical characterization it showed with changes in
properties, reduction in drug content and reduction
in in vitro drug release.

Table 9: In Vivo results of Quercetin dispersible tablet (Formulation F6) for anticancer activity.

12

Sr. No.

Compound

Concentration (µG)

O.D. at 492nm

% of cell lysis

1.

QF

10

3.004

100%

2.

QF

20

3.240

100%

3.

QF

30

3.500

100%

4.

Control

-

0.564

No lysis

IC50
Very <10 µG
-
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Table 10: Stability studies – In Vitro release studies of selected formulation F6 % release at 4o C±2oC/60%RH ±5%, 25ºC± 2oC/65%RH
± 5% and 37oC±2oC/65%RH±5%.
Before Stability Time In Minutes
38.09
44.08
53.84
66.66
72.72
75.76
88.70
98.25

5
10
15
20
30
40
50
60

%Release at 4o C ±2o
C/60%RH ±5%
35.25
42.08
50.84
65.66
67.72
70.76
82.70
95.25

%Release at 25o C ±2o C/ %Release at 37o C ±2o
65%RH ± 5 %.
C/65%RH±5%
35.50
36.02
42.42
42.70
51.01
51.80
66.02
66.85
68.03
68.88
71.05
71.87
82.75
83.01
96.05
96.25

7. Conclusion
Oral dispersible tablets (ODT) of Quercetin were
successfully prepared by using direct compression
method. The various advantages of ODT will
surely enhance the patient compliance, low dosing,
and rapid onset of action, increased solubility due
to complexation with soluplus, increased absorption
of drug good stability. From this study, it can be
concluded that the prepared dispersible tablets
showed better disintegration and drug release of
formulation F6 disintegrated within a few seconds;
thereby enhancing absorption, and it shows
anticancer activity in lung carcinoma
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